share_log

Needham Maintains Buy on AtriCure, Lowers Price Target to $44

Benzinga ·  Jan 4 06:27

Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $49 to $44.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment